Pseudovirus News and Research

RSS

Discovery of new receptor that interacts with SARS-CoV-2 spike, suppresses infection

Researchers recently conducted a study to identify host factors affecting cellular interactions of the SARS-CoV-2 spike protein.

16 Nov 2021

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

A new study has described the molecular basis of the neutralization potency and breadth of nanobodies.

16 Nov 2021

Rapid finger stick test to detect antibodies against SARS-CoV-2 variants

A new preprint reports a semi-quantitative test that can measure neutralizing antibodies to the SARS-CoV-2 pathogen at the point of care, using a finger stick or venipuncture blood.

16 Nov 2021

Deficient spike-specific T cell responses and inability to neutralize SARS-CoV-2 variants 12 month post-infection

Researchers conducted a comprehensive, longitudinal, long-term immune study, including functional assays to assess immune fitness against antigenically different VoC. The study is currently available on the preprint server medRxiv* while awaiting peer review.

15 Nov 2021

Potential COVID-19 nasal spray vaccine shows promise in mice

A single sniff may one day be all it takes to immunize yourself against COVID-19.

15 Nov 2021

Detection of a coronavirus similar to SARS-CoV-2 in Cambodian bats

Now, a new study published in the journal Nature Communications reports the identification of SARS-CoV-2 related coronaviruses in two horseshoe bats sampled in Cambodia in 2010.

15 Nov 2021

Enhanced neutralizing antibody and T-cell responses by DNA-based vaccine encoding SARS-CoV-2 spike protein

Researchers from VaxiGen have been investigating the potential for a DNA vaccine boost to VP vaccines against coronavirus disease 2019.

9 Nov 2021

COVID-19 drug candidate with wide-ranging antiviral activity

A new study investigated the antiviral activity and mechanism of action of Brilacidin against multiple human coronaviruses.

9 Nov 2021

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Scientists from Northwestern University, USA, have recently developed a high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

8 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

26 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021